Streetbeat News

Analyst Ratings

EQT

Citigroup analyst Scott Gruber has upgraded EQT from Neutral to Buy and increased the price target from $37 to $44.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 2:08 pm

NGG

Citigroup analyst Jenny Ping has downgraded National Grid (NYSE:NGG) from Buy to Neutral, indicating a change in the investment outlook for the company.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 2:06 pm

LQDA

LifeSci Capital has initiated coverage on Liquidia with an Outperform rating and set a price target of $30.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 2:04 pm

TWO

Four analysts have recently published ratings on Two Harbors Investment Corp (NYSE:TWO), showing a range of sentiments from bullish to indifferent. The average 12-month price target has increased by 6.84% to $14.69. Despite a 53.93% decline in revenue growth, Two Harbors Inv maintains strong profitability with a net margin of 40.33% and a sound financial structure.

Portfolio Pulse from Benzinga Insights

October 03, 2024 | 2:01 pm

STLA

Barclays analyst Henning Cosman has downgraded Stellantis (NYSE:STLA) from Overweight to Equal-Weight, indicating a more neutral stance on the stock.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 2:00 pm

BKR

Analysts have varied ratings for Baker Hughes (NASDAQ:BKR), with a mix of bullish and bearish sentiments. The average 12-month price target has increased by 4.57% to $43.21. Recent analyst actions include both raises and lowers in ratings and price targets, reflecting dynamic market conditions. Baker Hughes shows strong revenue growth and net margin but faces challenges with return on equity.

Portfolio Pulse from Benzinga Insights

October 03, 2024 | 2:00 pm

RCUS

Arcus Biosciences (NYSE:RCUS) received mixed analyst ratings over the past three months, with a majority being somewhat bullish. Analysts provided a 12-month price target range of $23.00 to $30.00, with an average target of $27.00, down from a previous average of $29.75. The company, a clinical-stage biopharmaceutical firm, reported a 34.48% revenue growth rate but faces challenges with a negative net margin and ROA.

Portfolio Pulse from Benzinga Insights

October 03, 2024 | 2:00 pm

EVGO

JP Morgan analyst Bill Peterson has upgraded EVgo (NASDAQ:EVGO) from Neutral to Overweight, setting a price target of $7.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 1:57 pm